UroGen Pharma
Urologic Oncology Therapies
StartupUroGen Pharma is a Ra'anana-based startup in the Health Tech & Life Sciences sector, established in 2004. Urologic Oncology Therapies. The company has raised a total of $522.2M across 10 funding rounds, currently at the Public stage. UroGen Pharma was founded by Asher Holtzer. Key investors include Great Point Partners, RA Capital Management, Acorn Bioventures, among 8 total investors. The company has 201-500 employees. Core technologies: Biologicals, Cells.
With $522.2M in total funding, UroGen Pharma is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees201-500
- HQRa'anana
- DistrictCenter District
- Last Round$107.5M
- Great Point PartnersLead
- RA Capital ManagementLead
- Acorn Bioventures
8 investors total
Asher HoltzerFounder
209 articles covered by sources including finance.yahoo.com,
www.clinicaltrialsarena.com,
www.biopharmadive.com,
www.businesswire.com,
www.pharmaceutical-technology.com.
What does UroGen Pharma do?
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated. The company has developed RTGel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained-release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's lead product candidates, UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), are designed to potentially remove tumors by nonsurgical means and to treat several forms of non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer, respectively. In April 2020, the FDA accepted for filing UroGen's new drug application for UGN-101 (mitomycin gel) for the treatment of low-grade upper-tract urothelial cancer. UGN-101 will be the only drug available for this type of cancer.
How much funding has UroGen Pharma raised?
UroGen Pharma has raised $522.2M in total funding across 10 rounds. The company is currently at the Public stage. Key investors include Great Point Partners, RA Capital Management, Acorn Bioventures.
Who founded UroGen Pharma?
UroGen Pharma was founded in 2004 by Asher Holtzer (Founder).
What sector is UroGen Pharma in?
UroGen Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Drug Delivery, with core technologies in Biologicals, Cells. Target customers: Consumers, Demographics & Family, Men, Healthcare & Life Sciences, Healthcare, Patients, Life Sciences, Pharmaceuticals.
Where is UroGen Pharma located?
UroGen Pharma is based in Ha-Ta'asiya Street 9, Ra'anana, Israel, Center District. The company also has offices abroad.